David S. Knopman

David S. Knopman

Auto-generated profile, based on publicly available information

David S. Knopman

Department of Neurology, Mayo Clinic, Rochester, MN

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 May 2021 in Nature Reviews Disease Primers
Verified
Journal Article
Closed access
PDF file
DKDavid S. Knopman
David S. Knopman
HAHelene Amieva
Helene Amieva
RPRonald C. Petersen
Ronald C. Petersen
GCGäel Chételat
Gäel Chételat
DHDavid M. Holtzman
David M. Holtzman
DJDavid T. Jones
David T. Jones

1 December 2009 in Archives of Neurology
Verified
Journal Article
Open access
PDF file
RPRonald C. Petersen
Ronald C. Petersen
RRRosebud O. Roberts
Rosebud O. Roberts
DKDavid S. Knopman
David S. Knopman
BBBradley F. Boeve
Bradley F. Boeve
YGYonas E. Geda
Yonas E. Geda
CJClifford R. Jack
Clifford R. Jack
In the past 10 years, there has been a virtual explosion in the literature concerning the construct of mild cognitive impairment. The interest in this topic demonstrates the increasing emphasis on the identification of the earliest features of cognitive disorders such as Alzheimer disease and other dementias. Mild cognitive impairment represents the earliest clinical features of these conditions and, hence, has become a focus of clinical, epidemiologic, neuroimaging, biomarker, neuropathological, disease mechanism, and clinical trials research. This review summarizes the progress that has been made while also recognizing the challenges that remain.

11 April 2017 in JAMA
Verified
Journal Article
Open access
PDF file
RGRebecca F. Gottesman
Rebecca F. Gottesman
ASAndrea L. C. Schneider
Andrea L. C. Schneider
YZYun Zhou
Yun Zhou
JCJosef Coresh
Josef Coresh
EGEdward Green
Edward Green
TMTom Mosley
Tom Mosley
Increasing evidence supports a role of vascular risk factors and markers in the development and etiology of Alzheimer disease (AD). Most major vascular risk factors, including hypertension,1-4 diabetes,5 smoking,3,6 and hypercholesterolemia,4,7 particularly when measured in midlife, have been associated with risk of dementia generally and AD specifically. Whether these risk factors directly increase the neurodegeneration specifically associated with AD (such as through increasing amyloid deposition) or lead to other cerebral changes that, in conjunction with ongoing neurodegeneration, might worsen cognitive performance is not yet known.

23 February 2022 in Nature
Verified
Journal Article
Open access
PDF file
XMX. Rosa Ma
X. Rosa Ma
MPMercedes Prudencio
Mercedes Prudencio
YKYuka Koike
Yuka Koike
SVSarat C. Vatsavayai
Sarat C. Vatsavayai
GKGaram Kim
Garam Kim
AGAaron D. Gitler
Aaron D. Gitler
A hallmark pathological feature of the neurodegenerative diseases amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) is the depletion of RNA-binding protein TDP-43 from the nucleus of neurons in the brain and spinal cord1. A major function of TDP-43 is as a repressor of cryptic exon inclusion during RNA splicing2–4. Single nucleotide polymorphisms in UNC13A are among the strongest hits associated with FTD and ALS in human genome-wide association studies5,6, but how those variants increase risk for disease is unknown. Here we show that TDP-43 represses a cryptic exon-splicing event in UNC13A. Loss of TDP-43 from the nucleus in human brain, neuronal cell lines and motor neurons derived from induced pluripotent stem cells resulted in the inclusion of a cryptic exon in UNC13A mRNA and reduced UNC13A protein expression. The top variants associated with FTD or ALS risk in humans are located in the intron harbouring the cryptic exon, and we show that they increase UNC13A cryptic exon splicing in the face of TDP-43 dysfunction. Together, our data provide a direct functional link between one of the strongest genetic risk factors for FTD and ALS (UNC13A genetic variants), and loss of TDP-43 function.

1 November 2003 in Journal of Neuropathology & Experimental Neurology
Verified
Journal Article
Open access
PDF file
DKD. S. Knopman
D. S. Knopman
JPJ. E. Parisi
J. E. Parisi
ASA. Salviati
A. Salviati
MFM. Floriach-Robert
M. Floriach-Robert
BBB. F. Boeve
B. F. Boeve
RPR. C. Petersen
R. C. Petersen
Despite general agreement about the boundaries of Alzheimer disease (AD), establishing a maximum limit for Alzheimer-type pathology in cognitively intact individuals might aid in defining more precisely the point at which Alzheimer pathology becomes clinically relevant. In this study, we examined the neuropathological changes in the brains of 39 longitudinally followed, cognitively normal elderly individuals (24 women, 15 men; age range 74–95, median 85 years). Neuropathological changes of the Alzheimer type were quantified by determining neurofibrillary tangle (NFT) staging by the method of Braak and Braak and by quantification of the abundance of diffuse, cored, and neuritic plaque burden using the scheme developed by the Consortium to Establish a Registry for Alzheimer Disease (CERAD). Vascular, Lewy body, and argyrophilic grain pathology were also assessed. We found 34 subjects (87%) with a Braak stage 32 subjects (82%) with less than moderate numbers of cored plaques and 37 subjects (95%) with less than moderate numbers of tau-positive neuritic plaques. Many subjects had moderate or frequent diffuse plaques (n = 19, 49%). By the National Institute on Aging-Reagan Institute (NIA-RI) criteria, none of our cases met criteria for high “likelihood” of AD. Four met NIA-RI criteria for intermediate “likelihood.” Seven cases met CERAD criteria for possible AD. Nineteen met Khachaturian criteria for AD. Only 1 subject had neocortical Lewy bodies. Small, old infarcts were common, but no subjects had more than 2 of these and none had a single large infarction. Thus, the majority of individuals who are cognitively normal near the time of their death have minimal amounts of tau-positive neuritic pathology (Braak stage <IV and neuritic plaques <6 per ×100 field in the most affected neocortical region). The few subjects with more severe AD pathology can be expected based on incidence rates of AD in the very elderly.

1 November 2020 in Alzheimer's & Dementia
Verified
Journal Article
Open access
PDF file
DKDavid S. Knopman
David S. Knopman
DJDavid T. Jones
David T. Jones
MGMichael D. Greicius
Michael D. Greicius
Aducanumab recently underwent two large phase III clinical trials that were stopped prematurely by the sponsor Biogen. One trial was trending positive while the other showed no benefits from aducanumab. Post hoc analyses led the sponsor to assert that there was a sufficient efficacy signal to justify a new drug application as a treatment for Alzheimer's disease. The sponsor claimed that subsets of participants receiving sufficiently high doses of aducanumab demonstrated benefits in both trials. In contrast, we identified alternative accounts for the apparent drug benefits in post hoc subgroups that are unrelated to dose effects. Biomarker data were consistent with target engagement, but no evidence was presented to correlate biomarker changes to cognitive benefits. Our analysis supports the conduct of a third, phase III trial with high‐dose aducanumab. Aducanumab's efficacy as a treatment for the cognitive dysfunction in Alzheimer's disease cannot be proven by clinical trials with divergent outcomes.